The thromboplastic activity of Russell's viper venom was first recognized to be of practical value when it was used by Macfarlane and Barnett (1934) as a powerful local haemostatic agent in the treatment of haemophilia.
(RECEIVED FOR PUBLICATION JANUARY 5, 1954) The thromboplastic activity of Russell's viper venom was first recognized to be of practical value when it was used by Macfarlane and Barnett (1934) as a powerful local haemostatic agent in the treatment of haemophilia. Fullerton (1940) substituted Russell's viper venom for rabbit-brain thromboplastin in his modification of Quick's one-stage prothrombin time, since viper venom could be obtained in a more convenient and more stable form than brain extract It soon became apparent, however, that the two methods gave widely different results. Wilson (1947) and many other workers found that in cases treated with dicoumarol much higher plasma prothrombin values were obtained with venom than with brain thromboplastin, and, in fact, Fullerton's modification could be dangerous, since it gave inadequate warning of prothrombin values low enough to cause haemorrhage.
It has been shown by Macfarlane, Trevan, and Attwood (1941) that a lipoid substance in the plasma is necessary for the action of viper venom, and an excess of lipoid, such as occurs after a fatty meal, shortens the prothrornbin time with venom but not with brain thromboplastin (Fullerton and Anastasopoulos, 1949) .
A further source of the difference in action of the two thromboplastins became apparent when it was recognized that the one-stage prothrombin time measured not only prothrombin but also the two accelerator factors which have been termed Factor V (Owren, 1947) and Factor VII (Koller, Loeliger, and Duckert, 1951 Tudhope (1953) that the main action of the anti-coagulant drug " tromexan " is to depress Factor VII and not prothrombin, at least in the initial period of treatment. Prothrombin times were carried out on tromexan plasma using " difco " and " stypven" thromboplastins in parallel, and the results expressed as " prothrombin " percentage by reference to saline dilution curves. Plasmas were investigated on different days after the beginning of therapy as shown in Table I . It can be seen that much higher values are given with " stypven " than with " difco," especially in the earlier period of therapy. The closer approximation of the two methods in the later days may be due to the fact that prothrombin also is reduced if tromexan is continued for this length of time.
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Hunter and Tudhope (1953) have shown that normal serum containing Factor VII has an accelerator action on tromexan plasma and the following experiment shows that " stypven" possesses similar accelerator activity. Tromexan plasma was mixed with stypven solution, l in 20,000, in the proportion of 9 to 1 and prothrombin times were carried out by Quick's method on successive days of therapy (Table IT) . The powerful accelerator action produced by 10 % of 1 in 20,000 solution of " stypven" is again most marked in the earlier days of therapy. Effect of Stypven on Plasma of Congenital Factor VII Deficiency.-The case of congenital Factor VII deficiency used in these experiments has been fully described elsewhere (Jenkins, 1954) .
One-stage prothrombin times were measured on several occasions on plasma from this case using " difco " and " stypven" in parallel (Table III) . For purposes of comparison the prothrombin times are expresse.d as " prothrombin " percentage by reference to dilution curves, although it has been shown by the two-stage prothrombin test that in reality only Factor VII is deficient. The corrective action of " stypven " on the prothrombin time was demonstrated by mixing the patient's plasma with " stypven" in the proportion of 9 to I and measuring Quick's prothrombin times. The results were compared with the corrective effect of similar amounts of normal serum and normal plasma, both of which contain Factor VII or its precursor (Table IV) .
The-powerful effect of a 1 in 20,000 solution of " stypven" is shown and even in a dilution of 1 in 200,000 the action is comparable with normal Macfarlane, 1953 ) and it appears to be identical with the " co-thromboplastin " described by Mann and Hum (1951) .
Brain thromboplastin requires Factor VII for its action, whereas Russell's viper venom is more complete in its thromboplastic activity because of the co-thromboplastin or accelerator which it contains. This property explains the powerful haemostatic action of venom but renders it insensitive to the reduction of Factor VII which occurs after the administration of dicoumarol or tromexan.
For this reason, " stypven" is useless in the control of treatment with these drugs.
Since rabbit brain extract and viper venom differ in this manner, it is possible that the divergent results obtained by various workers using other sources of thromboplastin, such as human placenta or ox lung, are related to the nature or quantity of the co-thromboplastin factors in these tissue extracts.
The action of rabbit brain extract is the best known of all these tissue preparations and for this reason it is to be preferred for general use. Summary Russell's viper venom is shown to have a powerful accelerator action as part of its thromboplastic activity.
The accelerator is closely similar to Factor VII and is probably a co-thromboplastin.
Differences in the thromboplastic activity of other tissue extracts may be related to the co-thromboplastin present.
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